TWI537262B - 供治療糖尿病使用之新穎１，２，３，４－四氫喹啉衍生物 - Google Patents
供治療糖尿病使用之新穎１，２，３，４－四氫喹啉衍生物 Download PDFInfo
- Publication number
- TWI537262B TWI537262B TW101128102A TW101128102A TWI537262B TW I537262 B TWI537262 B TW I537262B TW 101128102 A TW101128102 A TW 101128102A TW 101128102 A TW101128102 A TW 101128102A TW I537262 B TWI537262 B TW I537262B
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- diabetes
- pharmaceutically acceptable
- acceptable salt
- treatment
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims 5
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical class C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 2
- VTZDPQGGOUEESD-UHFFFAOYSA-N 4-hexynoic acid Chemical compound CC#CCCC(O)=O VTZDPQGGOUEESD-UHFFFAOYSA-N 0.000 claims 1
- -1 8-methoxy-3,4-dihydro-2H-quinolin-1-yl Chemical group 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161524462P | 2011-08-17 | 2011-08-17 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201319060A TW201319060A (zh) | 2013-05-16 |
| TWI537262B true TWI537262B (zh) | 2016-06-11 |
Family
ID=46690732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW101128102A TWI537262B (zh) | 2011-08-17 | 2012-08-03 | 供治療糖尿病使用之新穎１，２，３，４－四氫喹啉衍生物 |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US8431706B2 (enExample) |
| EP (1) | EP2744806B1 (enExample) |
| JP (1) | JP5903162B2 (enExample) |
| KR (1) | KR101570624B1 (enExample) |
| CN (1) | CN103687856B (enExample) |
| AP (1) | AP3589A (enExample) |
| AR (1) | AR087451A1 (enExample) |
| AU (1) | AU2012295372A1 (enExample) |
| BR (1) | BR112014003079A2 (enExample) |
| CA (1) | CA2843474C (enExample) |
| CL (1) | CL2014000357A1 (enExample) |
| CO (1) | CO6880069A2 (enExample) |
| CR (1) | CR20140052A (enExample) |
| DO (1) | DOP2014000018A (enExample) |
| EA (1) | EA022165B1 (enExample) |
| EC (1) | ECSP14013211A (enExample) |
| ES (1) | ES2578165T3 (enExample) |
| GT (1) | GT201400022A (enExample) |
| IL (1) | IL230635A (enExample) |
| IN (1) | IN2014MN00191A (enExample) |
| MA (1) | MA35351B1 (enExample) |
| MX (1) | MX2014001832A (enExample) |
| PE (1) | PE20140831A1 (enExample) |
| PH (1) | PH12014500366A1 (enExample) |
| SG (1) | SG11201401793PA (enExample) |
| TN (1) | TN2014000058A1 (enExample) |
| TW (1) | TWI537262B (enExample) |
| UA (1) | UA110983C2 (enExample) |
| WO (1) | WO2013025424A1 (enExample) |
| ZA (1) | ZA201400705B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3068788A1 (en) | 2013-11-14 | 2016-09-21 | Cadila Healthcare Limited | Novel heterocyclic compounds |
| EP3076959B1 (en) | 2013-12-04 | 2018-07-04 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| US10059667B2 (en) | 2014-02-06 | 2018-08-28 | Merck Sharp & Dohme Corp. | Antidiabetic compounds |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| CN109666027A (zh) * | 2017-10-17 | 2019-04-23 | 中国科学院上海药物研究所 | 一类酰胺结构的gpr40激动剂化合物及其用途 |
| WO2019134984A1 (en) | 2018-01-08 | 2019-07-11 | Celon Pharma S.A. | 3-phenyl-4-hexynoic acid derivatives as gpr40 agonists |
| KR102708681B1 (ko) | 2018-02-13 | 2024-09-26 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| EP4600247A3 (en) | 2018-04-19 | 2025-11-19 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| UA126421C2 (uk) | 2018-07-13 | 2022-09-28 | Гіліад Сайєнсіз, Інк. | Інгібітори pd-1/pd-l1 |
| US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| WO2020242252A1 (ko) | 2019-05-31 | 2020-12-03 | 현대약품 주식회사 | 3-(4-(벤질옥시)페닐)헥스-4-이노익산 유도체의 신규 결정형 |
| TWI751585B (zh) * | 2019-06-28 | 2022-01-01 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| BR112022006546A2 (pt) | 2019-10-07 | 2022-08-30 | Kallyope Inc | Agonistas de gpr119 |
| WO2021083270A1 (zh) * | 2019-10-31 | 2021-05-06 | 中国石油化工股份有限公司 | 负载型催化剂及其制备方法和应用 |
| CA3173731A1 (en) | 2020-02-28 | 2021-09-02 | Kallyope, Inc. | Gpr40 agonists |
| CN116323608A (zh) | 2020-05-19 | 2023-06-23 | 卡尔优普公司 | Ampk活化剂 |
| EP4172162A4 (en) | 2020-06-26 | 2024-08-07 | Kallyope, Inc. | AMPK ACTIVATORS |
| KR102699076B1 (ko) * | 2021-04-01 | 2024-08-27 | 현대약품 주식회사 | 3-(4-(벤질옥시)페닐)헥스-4-이노익산 유도체의 신규 용도 |
| CN115317484B (zh) * | 2022-08-26 | 2023-07-18 | 北京箭牧科技有限公司 | Ly2922470在制备预防或治疗脑血管疾病或组织缺血再灌注损伤药物中的应用 |
| CN115671105B (zh) * | 2022-11-22 | 2023-10-27 | 北京箭牧科技有限公司 | Ly2922470在制备预防或治疗肾脏疾病药物中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GT199900147A (es) * | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
| US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
| EP1379523B1 (en) * | 2001-03-27 | 2005-07-27 | Actelion Pharmaceuticals Ltd. | 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists |
| EA011010B1 (ru) * | 2004-02-27 | 2008-12-30 | Эмджен, Инк. | Соединения, модулирующие рецептор gpr40, фармацевтическая композиция, способ лечения заболеваний, чувствительных к модулированию рецептора gpr40 (варианты), способ модулирования функции gpr40 (варианты) и способ модулирования циркулирующей концентрации инсулина |
| WO2005087710A1 (ja) * | 2004-03-15 | 2005-09-22 | Takeda Pharmaceutical Company Limited | アミノフェニルプロパン酸誘導体 |
| EP2253315A1 (en) * | 2004-03-30 | 2010-11-24 | Takeda Pharmaceutical Company Limited | Alkoxyphenylpropanoic acid derivatives |
| AR078522A1 (es) | 2009-10-15 | 2011-11-16 | Lilly Co Eli | Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis |
| AR078948A1 (es) | 2009-11-30 | 2011-12-14 | Lilly Co Eli | Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes |
-
2012
- 2012-08-03 AR ARP120102845A patent/AR087451A1/es unknown
- 2012-08-03 TW TW101128102A patent/TWI537262B/zh not_active IP Right Cessation
- 2012-08-09 CN CN201280036072.0A patent/CN103687856B/zh not_active Expired - Fee Related
- 2012-08-09 MX MX2014001832A patent/MX2014001832A/es unknown
- 2012-08-09 CA CA2843474A patent/CA2843474C/en not_active Expired - Fee Related
- 2012-08-09 EA EA201490269A patent/EA022165B1/ru not_active IP Right Cessation
- 2012-08-09 AU AU2012295372A patent/AU2012295372A1/en not_active Abandoned
- 2012-08-09 UA UAA201401073A patent/UA110983C2/uk unknown
- 2012-08-09 PE PE2014000218A patent/PE20140831A1/es not_active Application Discontinuation
- 2012-08-09 PH PH1/2014/500366A patent/PH12014500366A1/en unknown
- 2012-08-09 KR KR1020147003634A patent/KR101570624B1/ko not_active Expired - Fee Related
- 2012-08-09 JP JP2014526078A patent/JP5903162B2/ja not_active Expired - Fee Related
- 2012-08-09 US US13/570,342 patent/US8431706B2/en not_active Expired - Fee Related
- 2012-08-09 AP AP2014007436A patent/AP3589A/xx active
- 2012-08-09 SG SG11201401793PA patent/SG11201401793PA/en unknown
- 2012-08-09 ES ES12748334.5T patent/ES2578165T3/es active Active
- 2012-08-09 BR BR112014003079A patent/BR112014003079A2/pt not_active IP Right Cessation
- 2012-08-09 WO PCT/US2012/050051 patent/WO2013025424A1/en not_active Ceased
- 2012-08-09 EP EP12748334.5A patent/EP2744806B1/en active Active
-
2013
- 2013-01-30 CR CR20140052A patent/CR20140052A/es unknown
-
2014
- 2014-01-23 IL IL230635A patent/IL230635A/en not_active IP Right Cessation
- 2014-01-28 DO DO2014000018A patent/DOP2014000018A/es unknown
- 2014-01-29 ZA ZA2014/00705A patent/ZA201400705B/en unknown
- 2014-01-30 IN IN191MUN2014 patent/IN2014MN00191A/en unknown
- 2014-02-10 TN TNP2014000058A patent/TN2014000058A1/en unknown
- 2014-02-13 CL CL2014000357A patent/CL2014000357A1/es unknown
- 2014-02-13 GT GT201400022A patent/GT201400022A/es unknown
- 2014-02-13 MA MA36755A patent/MA35351B1/fr unknown
- 2014-02-14 CO CO14032116A patent/CO6880069A2/es active IP Right Grant
- 2014-02-17 EC ECSP14013211 patent/ECSP14013211A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW201319060A (zh) | 供治療糖尿病使用之新穎１，２，３，４－四氫喹啉衍生物 | |
| JP5524091B2 (ja) | エストロゲン関連受容体モジュレータ化合物及びその使用 | |
| TW201141866A (en) | Novel spiropiperidine compounds | |
| US10035819B2 (en) | PPAR agonists and methods of use thereof | |
| US6787556B1 (en) | Benzoic acid derivatives for the treatment of diabetes mellitus | |
| KR101624020B1 (ko) | 퀴놀리논 유도체 | |
| CN102186825A (zh) | 芳基gpr120受体激动剂和其用途 | |
| JPWO2011052756A1 (ja) | 新規３−ヒドロキシ−５−アリールイソキサゾール誘導体 | |
| TW200848026A (en) | Dihydroindazole compounds useful in treating iron disorders | |
| CA2469048A1 (en) | Quinolinones as prostaglandin receptor ligands | |
| TW201722919A (zh) | 過氧化物酶體增生劑活化之受體（ppar）促效劑其化合物其醫藥組合物及其使用方法 | |
| TW201625610A (zh) | 萘啶二酮（ｎａｐｈｔｈｙｒｉｄｉｎｅｄｉｏｎｅ）衍生物 | |
| TW200812989A (en) | Novel heterocyclic diphenyl ethers | |
| KR101662592B1 (ko) | 퍼옥시좀 증식체-활성화 수용체 하위유형 델타에 대한 흥분 효과를 가진 화합물, 이의 제조방법 및 이의 용도 | |
| Furukawa et al. | Synthesis and biological evaluation of novel (−)-cercosporamide derivatives as potent selective PPARγ modulators | |
| EP3259256B1 (en) | Compounds and methods for inducing browning of white adipose tissue | |
| CA3210977A1 (en) | Small molecule activators of yap transcriptional activity for regenerative organ repair | |
| WO2004074284A1 (en) | Oxazole-derivatives as ppar agonists | |
| WO2024061172A1 (zh) | 一种脯氨酰羟化酶抑制剂及其用途 | |
| WO2014117292A1 (zh) | 酰胺类化合物及其制备方法、药物组合物和用途 | |
| CN108003074B (zh) | 联苯羧酸类化合物及其制备方法和用途 | |
| NZ621248B2 (en) | A Novel 1,2,3,4-Tetrahydroquinoline Derivative Useful for the Treatment of Diabetes | |
| WO2019146670A1 (ja) | 光応答性Ｓｍｏｏｔｈｅｎｅｄリガンド | |
| HK1241362B (en) | Compounds and methods for inducing browning of white adipose tissue |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |